Poster Presentation ESA-SRB-ANZBMS 2024 in conjunction with ENSA

Hormonal rollercoasters and steroid stunts: NC-CAH journey through pregnancy  (#607)

Ummul Mahfuza 1 2 , Vincent Wong 1 3 , Namson Lau 1 3 4 , Tang Wong 3 5 6 7 , Sue-Lyn Lau 5 8 , Hamish Russell 1 3
  1. Liverpool Hospital, Liverpool, NSW, Australia
  2. University of Sydney , Sydney
  3. University of New South Wales, Sydney , NSW
  4. Royal Prince Alfred Hospital , Sydney , NSW
  5. Blacktown Hospital, Sydney, NSW
  6. The Prince of Wales Hospital, Sydney , NSW
  7. Western Sydney University , Sydney , NSW
  8. Westmead Hospital, Sydney, NSW

Aims: This case study aims to describe the management of Non-Classical Congenital Adrenal Hyperplasia (NC-CAH) in a 37-year-old Iranian female, Mrs. M H, focusing on the challenges of fertility and pregnancy management. The goal is to provide insights into the effective use of glucocorticoid therapy to manage hyperandrogenism and improve fertility outcomes.

Methods: The patient, diagnosed with NC-CAH at age 28 following multiple miscarriages, was managed with glucocorticoid therapy. Her diagnosis was confirmed through genetic testing, revealing compound heterozygous CYP21A2 gene mutations. Serial pregnancies were managed with different glucocorticoids: hydrocortisone in her first pregnancy, dexamethasone post-first pregnancy for hirsutism, and prednisone during her second and third pregnancies. Throughout her pregnancies, the patient’s androgen levels were monitored, and glucocorticoid dosages were adjusted accordingly.

Results: The patient successfully conceived and carried to term three pregnancies with the aid of glucocorticoid therapy. Her first pregnancy resulted in the birth of a healthy male child while on low-dose hydrocortisone. Post-pregnancy dexamethasone treatment effectively managed her hirsutism. During her second and third pregnancies, prednisone was used to manage hyperandrogenism, resulting in the birth of a healthy female child and a currently ongoing pregnancy. The patient's androgen levels were well-controlled during treatment, and stress dosing during labor ensured safe delivery.

Conclusion: Glucocorticoid therapy plays a critical role in managing fertility and pregnancy in women with NC-CAH. Early diagnosis, regular monitoring, and multidisciplinary management are essential for optimizing outcomes. This case underscores the importance of personalized glucocorticoid regimens to control androgen levels, prevent miscarriages, and support successful pregnancies. Genetic counseling for partners and stress dosing during labor are also vital components of care.

  1. Uslar T, Olmos R, Martínez-Aguayo A, Baudrand R. Clinical Update on Congenital Adrenal Hyperplasia: Recommendations from a Multidisciplinary Adrenal Program. J Clin Med. 2023 Apr 26;12(9):3128. doi: 10.3390/jcm12093128. PMID: 37176569; PMCID: PMC10179176.
  2. Witchel SF. Congenital Adrenal Hyperplasia. J Pediatr Adolesc Gynecol. 2017 Oct;30(5):520-534. doi: 10.1016/j.jpag.2017.04.001. Epub 2017 Apr 24. PMID: 28450075; PMCID: PMC5624825.
  3. Bidet, M., Bellanné-Chantelot, C., Galand-Portier, M. B., Golmard, J. L., Tardy, V., Morel, Y., Clauin, S., Coussieu, C., Boudou, P., Mowzowicz, I., Bachelot, A., Touraine, P., & Kuttenn, F. (2010). Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. The Journal of clinical endocrinology and metabolism, 95(3), 1182–1190. https://doi.org/10.1210/jc.2009-1383
  4. Feldman S, Billaud L , Thalabard JC, Raux-Demay MC, Mowszowicz I, Kuttenn F, Mauvais-Jarvis P 1992 Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency, . J Clin Endocrinol Metab 74:635–639
  5. C. Moran, R. Azziz, N. Weintrob, S. F. Witchel, V. Rohmer, D. Dewailly, J. A. M. Marcondes, M. Pugeat, P. W. Speiser, D. Pignatelli, B. B. Mendonca, T. A. S. Bachega, H. F. Escobar-Morreale, E. Carmina, F. Fruzzetti, F. Kelestimur, Reproductive Outcome of Women with 21-Hydroxylase-Deficient Nonclassic Adrenal Hyperplasia, The Journal of Clinical Endocrinology & Metabolism, Volume 91, Issue 9, 1 September 2006, Pages 3451–3456, https://doi.org/10.1210/jc.2006-0062
  6. Falhammar, H., Nordenström, A. Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome. Endocrine 50, 32–50 (2015). https://doi.org/10.1007/s12020-015-0656-0
  7. Livadas, S., & Bothou, C. (2019). Management of the Female With Non-classical Congenital Adrenal Hyperplasia (NCCAH): A Patient-Oriented Approach. Frontiers in Endocrinology (Lausanne), 10, 366–366. https://doi.org/10.3389/fendo.2019.00366
  8. Maher, J. Y., Gomez-Lobo, V., & Merke, D. P. (2023). The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum. Reviews in Endocrine & Metabolic Disorders, 24(1), 71–83. https://doi.org/10.1007/s11154-022-09770-5
  9. Elise M A Slob, Jacqueline U M Termote, Janna W Nijkamp, Hetty J van der Kamp, Erica L T van den Akker, Safety of Antenatal Predniso(lo)ne and Dexamethasone on Fetal, Neonatal and Childhood Outcomes: A Systematic Review, The Journal of Clinical Endocrinology & Metabolism, Volume 109, Issue 4, April 2024, Pages e1328–e1335, https://doi.org/10.1210/clinem/dgad547
  10. Keely, E., & Malcolm, J. (2012). Congenital adrenal hyperplasia in pregnancy: approach depends on who is the ‘patient.’ Obstetric Medicine, 5(4), 154–160. https://doi.org/10.1258/om.2012.120015